Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

Network Pharmacology and Integrated Molecular Docking Study on the Mechanism of the Therapeutic Effect of Fangfeng Decoction in Osteoarthritis

Author(s): Wenqiao Wang, Min Li, Hongzong Si and Zehui Jiang*

Volume 29, Issue 5, 2023

Published on: 23 February, 2023

Page: [379 - 392] Pages: 14

DOI: 10.2174/1381612829666230216095659

Price: $65

Abstract

Background: At present, there are no effective pharmacologic therapies for attenuating the course of osteoarthritis (OA) in humans and current therapies are geared to mitigating symptoms. Fangfeng decoction (FFD) is a traditional Chinese medicine prescribed for the treatment of OA. In the past, FFD has achieved positive clinical outcomes in alleviating the symptoms of OA in China. However, its mechanism of action has not yet been clarified.

Objective: The objective of this study is to investigate and explore the mechanism of FFD and how the compound interacts with the target of OA; network pharmacology and molecular docking methods were applied in this study.

Methods: The active components of FFD were screened by Traditional Chinese Medicine Systems Pharmacology (TCMSP) database according to the inclusion criteria as oral bioactivity (OB) ≥ 30% and drug likeness (DL) ≥ 0.18. Then, gene name conversion was performed through the UniProt website. The related target genes of OA were obtained from the Genecards database. Core components, targets, and signaling pathways were obtained through compound-target-pathway (C-T-P) and protein-protein interaction (PPI) networks were built using Cytoscape 3.8.2 software. Matescape database was utilized to get gene ontology (GO) function enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment of gene targets. The interactions of key targets and components were analyzed by molecular docking in Sybyl 2.1 software.

Results: A total of 166 potential effective components, 148 FFD-related targets, and 3786 OA-related targets were obtained. Finally, 89 common potential target genes were confirmed. Pathway enrichment results showed that HIF-1 and CAMP signaling pathways were considered key pathways. The screening of core components and targets was achieved through the CTP network. The core targets and active components were obtained according to the CTP network. The molecular docking results showed that quercetin, medicarpin, and wogonin of FFD could bind to NOS2, PTGS2, and AR, respectively.

Conclusion: FFD is effective in the treatment of OA. It may be caused by the effective binding of the relevant active components of FFD to the targets of OA.

« Previous
[1]
Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet 2019; 393(10182): 1745-59.
[http://dx.doi.org/10.1016/S0140-6736(19)30417-9] [PMID: 31034380]
[2]
Felson DT, Nevitt MC. Epidemiologic studies for osteoarthritis: New versus conventional study design approaches. Rheum Dis Clin North Am 2004; 30(4): 783-97.
[http://dx.doi.org/10.1016/j.rdc.2004.07.005]
[3]
Pereira D, Peleteiro B, Araújo J, Branco J, Santos RA, Ramos E. The effect of osteoarthritis definition on prevalence and incidence estimates: A systematic review. Osteoarthritis Cartilage 2011; 19(11): 1270-85.
[http://dx.doi.org/10.1016/j.joca.2011.08.009] [PMID: 21907813]
[4]
Rai MF. Nip it in the bud: Potential for the early treatment of osteoarthritis. Osteoarthritis Cartilage 2021; 29(1): 6-7.
[http://dx.doi.org/10.1016/j.joca.2020.09.003] [PMID: 33075482]
[5]
Cornejo-Garcia J, Blanca-López N, Doña I, et al. Hypersensitivity reactions to non-steroidal anti-inflammatory drugs. Curr Drug Metab 2009; 10(9): 971-80.
[http://dx.doi.org/10.2174/138920009790711841] [PMID: 20214589]
[6]
Brosseau L, Wells GA, Kenny GP, et al. The implementation of a community-based aerobic walking program for mild to moderate knee osteoarthritis (OA): A knowledge translation (KT) randomized controlled trial (RCT): Part I: The Uptake of the Ottawa Panel clinical practice guidelines (CPGs). BMC Public Health 2012; 12(1): 871.
[http://dx.doi.org/10.1186/1471-2458-12-871] [PMID: 23061875]
[7]
Fang YUAN, Xiaojin HE, Jun S, Lin Z, Yiqun Z. Effect of gubi recipe in treating knee osteoarthritis with symptom of kidney deficiency and collateral obstruction. Zhongguo Shiyan Fangjixue Zazhi 2018; 24(07): 207-11.
[http://dx.doi.org/10.13422/j.cnki.syfjx.20180621]
[8]
Zhang M, Wu YC, Sun LP, Yu HF, Yang H, Wang ZF. The molecular mechanism of Gegen Qinlian Decoction in the treatment of radiation enteritis based on network pharmacology. Cancer Cell Research 2021; 8(32): 817-26.
[http://dx.doi.org/10.54762/ccr2021.817-826]
[9]
Shikov AN, Flisyuk EV, Obluchinskaya ED, Pozharitskaya ON. Pharmacokinetics of marine-derived drugs. Mar Drugs 2020; 18(11): 557.
[http://dx.doi.org/10.3390/md18110557] [PMID: 33182407]
[10]
Krishnan Y, Grodzinsky AJ. Cartilage diseases. Matrix Biol 2018; 71-72: 51-69.
[http://dx.doi.org/10.1016/j.matbio.2018.05.005] [PMID: 29803938]
[11]
Jiang J, Meng Y, Hu S, et al. Saikosaponin D: A potential therapeutic drug for osteoarthritis. J Tissue Eng Regen Med 2020; 14(8): 1175-84.
[http://dx.doi.org/10.1002/term.3090] [PMID: 32592611]
[12]
Saklatvala J. Inflammatory signaling in cartilage: MAPK and NF-kappaB pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis. Curr Drug Targets 2007; 8(2): 305-13.
[http://dx.doi.org/10.2174/138945007779940115] [PMID: 17305508]
[13]
Raman S, FitzGerald U, Murphy JM. Interplay of inflammatory mediators with epigenetics and cartilage modifications in osteoarthritis. Front Bioeng Biotechnol 2018; 6: 22.
[http://dx.doi.org/10.3389/fbioe.2018.00022] [PMID: 29594113]
[14]
Sohn D, Sokolove J, Sharpe O, et al. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4. Arthritis Res Ther 2012; 14(1): R7.
[http://dx.doi.org/10.1186/ar3555] [PMID: 22225630]
[15]
Stannus O, Jones G, Cicuttini F, et al. Circulating levels of IL-6 and TNF-α are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis Cartilage 2010; 18(11): 1441-7.
[http://dx.doi.org/10.1016/j.joca.2010.08.016] [PMID: 20816981]
[16]
Rhee J, Park SH, Kim SK, et al. Inhibition of BATF/JUN transcriptional activity protects against osteoarthritic cartilage destruction. Ann Rheum Dis 2017; 76(2): 427-34.
[http://dx.doi.org/10.1136/annrheumdis-2015-208953] [PMID: 27147707]
[17]
Wang T, He C. Pro-inflammatory cytokines: The link between obesity and osteoarthritis. Cytokine Growth Factor Rev 2018; 44: 38-50.
[http://dx.doi.org/10.1016/j.cytogfr.2018.10.002] [PMID: 30340925]
[18]
Khotib J, Utami NW, Gani MA, Ardianto C. The change of proinflammatory cytokine tumor necrosis factor α level in the use of meloxicam in rat model of osteoarthritis. J Basic Clin Physiol Pharmacol 2019; 30(6).
[http://dx.doi.org/10.1515/jbcpp-2019-0331] [PMID: 31837258]
[19]
Vizcarra C. New perspectives and emerging therapies for immune-mediated inflammatory disorders. J Infus Nurs 2003; 26(5): 319-25.
[http://dx.doi.org/10.1097/00129804-200309000-00008] [PMID: 14506365]
[20]
Abrahams VM, Cambridge G, Lydyard PM, Edwards JCW. Induction of tumor necrosis factor α production by adhered human monocytes: A key role for Fcγ receptor type IIIA in rheumatoid arthritis. Arthritis Rheum 2000; 43(3): 608-16.
[http://dx.doi.org/10.1002/1529-0131(200003)43:3<608::AID-ANR18>3.0.CO;2-G] [PMID: 10728755]
[21]
He X, Li SH, Wang XP, Mu YP. Theclinical application value ofFAM19A4/mir124-2 methylation test in hrHPV-positive women. cancer cell research 2022; 9(33): 836-40.
[http://dx.doi.org/10.54762/ccr2022.836-840]
[22]
Porée B, Kypriotou M, Chadjichristos C, et al. Interleukin-6 (IL-6) and/or soluble IL-6 receptor down-regulation of human type II collagen gene expression in articular chondrocytes requires a decrease of Sp1.Sp3 ratio and of the binding activity of both factors to the COL2A1 promoter. J Biol Chem 2008; 283(8): 4850-65.
[http://dx.doi.org/10.1074/jbc.M706387200] [PMID: 18065760]
[23]
Wei L, Chungen L, Xiaohong M, Limng C, Chen C, Ziyi Z. Mechanism of jinkui shenqi pill in treatment of osteoporosis based on network pharmacology. World Chinese Medicine 2021; 16(22): 3285-91.
[24]
Zhu X, Jun J. Effect of fangfeng decoction on the onset of wind- cold-dampness Bi knee osteoarthritis. Clin J Med Offic 2021; 49(02): 205-7.
[http://dx.doi.org/10.16680/j.1671-3826.2021.02.33]
[25]
Fan W. Clinical effect of fangfeng decoction on wind-cold-dampness Bi type knee osteoarthritis. Electronic Journal of Clinical Medical Literature 2019; 6(92): 167-8.
[http://dx.doi.org/10.16281/j.cnki.jocml.2019.92.128]
[26]
Renfei L. Analysis of therapeutic effect of fangfeng decoction on wind-cold-dampness Bi type knee osteoarthritis. World Latest Medicne Information 2017; 17(23): 92-4.
[27]
Haixu JIANG, Jie XU, Qingyi LU. Research progress of quercetin in treatment of rheumatoid arthritis. Zhongguo Shiyan Fangjixue Zazhi 2021; 27(05): 243-50.
[http://dx.doi.org/10.13422/j.cnki.syfjx.20210105]
[28]
Hu Y, Gui Z, Zhou Y, Xia L, Lin K, Xu Y. Quercetin alleviates rat osteoarthritis by inhibiting inflammation and apoptosis of chondrocytes, modulating synovial macrophages polarization to M2 macrophages. Free Radic Biol Med 2019; 145: 146-60.
[http://dx.doi.org/10.1016/j.freeradbiomed.2019.09.024] [PMID: 31550528]
[29]
Weitzmann M, Weitzmann MN. Quercetin, a potent suppressor of NF-κB and Smad activation in osteoblasts. Int J Mol Med 2011; 28(4): 521-5.
[http://dx.doi.org/10.3892/ijmm.2011.749] [PMID: 21769418]
[30]
Wang XC, Zhao NJ, Guo C, Chen JT, Song JL, Gao L. Quercetin reversed lipopolysaccharide-induced inhibition of osteoblast differentiation through the mitogen-activated protein kinase pathway in MC3T3-E1 cells. Mol Med Rep 2014; 10(6): 3320-6.
[http://dx.doi.org/10.3892/mmr.2014.2633] [PMID: 25323558]
[31]
Sirong S, Yang C, Taoran T, et al. Effects of tetrahedral framework nucleic acid/wogonin complexes on osteoarthritis. Bone Res 2020; 8(1): 6.
[http://dx.doi.org/10.1038/s41413-019-0077-4] [PMID: 32047705]
[32]
Tyagi AM, Gautam AK, Kumar A, et al. Medicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice. Mol Cell Endocrinol 2010; 325(1-2): 101-9.
[http://dx.doi.org/10.1016/j.mce.2010.05.016] [PMID: 20570709]
[33]
Mansoori MN, Raghuvanshi A, Shukla P, et al. Medicarpin prevents arthritis in post-menopausal conditions by arresting the expansion of TH17 cells and pro-inflammatory cytokines. Int Immunopharmacol 2020; 82: 106299.
[http://dx.doi.org/10.1016/j.intimp.2020.106299] [PMID: 32097846]
[34]
Kurumbail R, Kiefer JR, Marnett LJ. Cyclooxygenase enzymes: catalysis and inhibition. Curr Opin Struct Biol 2001; 11(6): 752-60.
[http://dx.doi.org/10.1016/S0959-440X(01)00277-9] [PMID: 11751058]
[35]
Newman AB, Brach JS. Gender gap in longevity and disability in older persons. Epidemiol Rev 2001; 23(2): 343-55.
[http://dx.doi.org/10.1093/oxfordjournals.epirev.a000810] [PMID: 12192741]
[36]
Sasano H, Uzuki M, Sawai T, et al. Aromatase in human bone tissue. J Bone Miner Res 1997; 12(9): 1416-23.
[http://dx.doi.org/10.1359/jbmr.1997.12.9.1416] [PMID: 9286757]
[37]
Luo X, Wang J, Wei X, Wang S, Wang A. Knockdown of lncRNA MFI2-AS1 inhibits lipopolysaccharide-induced osteoarthritis progression by miR-130a-3p/TCF4. Life Sci 2020; 240: 117019.
[http://dx.doi.org/10.1016/j.lfs.2019.117019] [PMID: 31678554]
[38]
Rogers EL, Reynard LN, Loughlin J. The role of inflammation-related genes in osteoarthritis. Osteoarthritis Cartilage 2015; 23(11): 1933-8.
[http://dx.doi.org/10.1016/j.joca.2015.01.003] [PMID: 26521739]
[39]
Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: Latest findings and interpretations. Ther Adv Musculoskelet Dis 2013; 5(2): 77-94.
[http://dx.doi.org/10.1177/1759720X12467868] [PMID: 23641259]
[40]
Xiong X, Zeng C, Liu L. Research of expression about HIF-1α in non-hodgkin’s lymphoma in children and its influence to prognosis and chemotherapy sensitivity. Cancer Cell Research 2016; 12: 290-3.
[41]
Qing L, Lei P, Liu H, et al. Expression of hypoxia-inducible factor-1α in synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritis. Exp Ther Med 2017; 13(1): 63-8.
[http://dx.doi.org/10.3892/etm.2016.3940] [PMID: 28123469]
[42]
Zeng CY, Wang XF, Hua FZ. HIF-1α in osteoarthritis: From pathogenesis to therapeutic implications. Front Pharmacol 2022; 13: 927126.
[http://dx.doi.org/10.3389/fphar.2022.927126] [PMID: 35865944]
[43]
Hu S, Zhang C, Ni L, et al. Stabilization of HIF-1α alleviates osteoarthritis via enhancing mitophagy. Cell Death Dis 2020; 11(6): 481.
[http://dx.doi.org/10.1038/s41419-020-2680-0] [PMID: 32587244]
[44]
Wang G, Li Y, Yang G, Yang T, He L, Wang Y. Cathelicidin antimicrobial peptide (CAMP) gene promoter methylation induces chondrocyte apoptosis. Hum Genomics 2021; 15(1): 24.
[http://dx.doi.org/10.1186/s40246-021-00321-8] [PMID: 33892795]
[45]
Morovic-Vergles J, Culo MI, Gamulin S, Culo F. Cyclic adenosine 5′-monophosphate in synovial fluid of rheumatoid arthritis and osteoarthritis patients. Rheumatol Int 2008; 29(2): 167-71.
[http://dx.doi.org/10.1007/s00296-008-0663-z] [PMID: 18695981]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy